Skip to main contentSkip to navigation
Sirius Investors
PsyBio Therapeutics Corp

PsyBio Therapeutics Corp

PSYBF
OTCHealthcare

PsyBio Therapeutics Corp (PSYBF) Investment Research Dashboard

About PsyBio Therapeutics Corp (PSYBF) stock analysis

Get live PSYBF stock price $0.00, comprehensive PsyBio Therapeutics Corp stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time PSYBF stock data and investment insights.

0.00
0.00%Today
Market Cap
1.27K
Volume
8.00K
52W High
0.01
52W Low
0.00

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.

Company Information

CEO
Evan Levine
Sector
Healthcare
Industry
Biotechnology
Employees
118

Contact Information

Address
1624 Washington Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.49) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for PsyBio Therapeutics Corp shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for PsyBio Therapeutics Corp
  • Investors should consider how PsyBio Therapeutics Corp fits within their overall portfolio allocation

Market Cap

1.27K

Beta

0.49

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

80/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+5.7%+6.1%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
86/100⭐⭐⭐⭐⭐
Healthcare+0.7%+3.3%+3.5%24.1
80/100⭐⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
56/100⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
56/100⭐⭐⭐⭐
Real Estate-0.5%-0.1%-1.6%29.2
43/100⭐⭐⭐
Energy-2.1%-5.8%-5.1%19.1
39/100⭐⭐
Utilities-1.0%-3.0%-5.9%26.8
28/100⭐⭐
Industrials+0.6%+1.7%-11.2%30.1
26/100⭐⭐
Consumer Cyclical+0.5%-0.4%-6.3%43.0
21/100
Technology+0.6%-2.3%-9.6%40.7
17/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.